Use of Rifaximin in Irritable Bowel Syndrome Treatment

Introduction and purpose of the work: Irritable Bowel Syndrome (IBS) affects up to 10% population. The deterioration in health-related quality life IBS patients has been shown be comparable to, perhaps even more severe than, other serious chronic organic diseases such as inflammatory bowel disease, diabetes, hypertension, end-stage renal disease. aim study is present a new method treatment.State knowledge: There are four main types IBS: Constipation-predominant (IBS-C), Diarrhea-predominant (IBS-D), Fluctuating (IBS-M), unclassified form (IBS-U). Disturbances entero-brain interactions play key role its multifactorial etiopathogenesis. In with IBS, quantitative qualitative disturbances composition intestinal microbiota can found. So far, it not possible clearly establish cause so there no possibility causal therapy effective cure. Both non-pharmacological methods drugs, including rifaximin α, have used therapy.Summary: Rifaximin positive effect on symptoms IBS. clinical trials conducted use for 2 weeks was associated reduction severity joint symptoms, bloating, abdominal pain discomfort, an improvement stool consistency within 4 12 weeks, did increase risk side effects. forms: predominant diarrhea, mixed unclassified, order reduce overall well flatulence / or 14-day α recommended.